Management of retinitis pigmentosa by Wharton’s jelly-derived mesenchymal stem cells: prospective analysis of 1-year results

Table 3 Comparison of measurements according to study timepoints

Measurements	T0	T1	T2	p	Comparison**
Measurements	X ± s.s.	X ± s.s.	X ± s.s.	p	Comparison**
ORT (μm)	101.29 ± 16.20	118.51 ± 17.36	118 ± 17.59	0.01*	T0 < T1, T2
HEZW (mm)	2.65 ± 1.12	2.70 ± 1.15	2.69 ± 1.16	0.01*	T0 < T1, T2
VEZW (mm)	2.51 ± 1.12	2.54 ± 1.14	2.53 ± 1.15	0.08	T0 = T1 = T2
BCVA (ETDRS)	70.5 ± 15.71	80.62 ± 16.26	79.97 ± 17.05	0.01*	T0 < T1, T2
FPDI (%)	8.00 ± 3.57	11.38 ± 4.84	11.59 ± 5.02	0.01*	T0 < T1, T2
ERG amplitude (mV)	2.37 ± 1.85	5.03 ± 4.21	4.53 ± 3.95	0.01*	T0 < T1, T2
ERG implicit time (ms)	43.28 ± 5.50	37.90 ± 7.88	38.58 ± 7.73	0.01*	T0 > T1, T2

**Repeated-measures analysis of variance test (rANOVA); *p < 0.05, statistically significant
HEZW horizontal ellipsoid zone width (mm); VEZW vertical ellipsoid zone width (mm); ORT outer retinal thickness (μm); BCVA best corrected visual acuity (ETDRS letters); FPDI fundus perimetry deviation index; ERG amplitude full-field flicker electroretinography; amplitude (mV); ERG implicit time full-field flicker electroretinography, implicit time (ms); T0 (baseline) just before the Wharton jelly-derived mesenchymal stem cell injection; T1 6th month after injection; T2 12th month after injection

ISSN: 1757-6512